Monday, June 15, 2026

Coupang Becomes A Trade Flashpoint as the United States Pressures Alarms Korean Lawmakers

The U.S. is using Coupang as leverage against South Korea, raising concerns in the National Assembly about trade implications.

King Donald’s Decree: Trump May Dictate Nuclear Summit With Kim, Blindsiding All Allies

Speculation grows over a potential surprise Trump-Kim summit during APEC, though South Korea remains skeptical about its likelihood.

North Korea’s New Defense Strategy: How Kim Jong Un Plans to Enhance Nuclear Deterrence in 2026

Kim Jong Un emphasizes nuclear deterrence in response to U.S. strategy, hinting at a new dual military approach at the upcoming Party Congress.

Tag: Medipost

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

CARTISTEM vs. Traditional Treatments: What Makes Medipost’s Stem Cell Therapy a Game-Changer?

Medipost to commercialize CARTISTEM in Japan using domestically produced media, enhancing supply chain stability and competitiveness.

Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial

Medipost's CARTISTEM therapy shows significant efficacy in Phase 3 trials for knee osteoarthritis in Japan, enhancing global competitiveness.

Medipost’s CARTISTEM® Completes Phase 3 Trials in Japan: What This Means for Knee Osteoarthritis Treatment

Medipost completes Phase 3 trial for CARTISTEM in Japan, targeting knee osteoarthritis treatment and planning U.S. trial enrollment soon.

Medipost’s Cartistem: Achieving 3000 Knee Cartilage Restoration Surgeries – A Game Changer for Osteoarthritis Treatment

Medipost's Cartistem therapy reaches 3,000 procedures for cartilage restoration, proving its safety and efficacy for knee osteoarthritis.

U.S. Surgeons Get Hands-On With Korea’s Game-Changing Stem Cell Therapy

Medipost's Cartistem® training program for U.S. orthopedic specialists enhances global collaboration and prepares for Phase 3 trials.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.